Actively Recruiting
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
Led by Elazıg Fethi Sekin Sehir Hastanesi · Updated on 2026-03-18
100
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.
CONDITIONS
Official Title
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6 18 years
- Diagnosis of Graves' disease (for the patient group)
- No known thyroid disease in healthy control participants
- Availability of optical coherence tomography (OCT) measurements and laboratory data
- Time interval between OCT examination and blood sampling 4 10 days
You will not qualify if you...
- Presence of glaucoma, optic neuropathy, or retinal vascular diseases
- Macular diseases, uveitis, or severe refractive error (high myopia >6 diopters)
- Diabetic retinopathy
- History of previous intraocular surgery
- History of active infection, malignancy, or systemic inflammatory disease
- Poor-quality OCT measurements (segmentation errors or low signal strength)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fethi Sekin City Hospital
Elâzığ, Elaziğ, Turkey (Türkiye)
Actively Recruiting
Research Team
S
SİNEM KESER, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here